Sex After Menopause: How Intimacy Changes and How to Thrive
Dr. Karla Loken is a board-certified OB/GYN with over two decades of clinical experience and a distinguished career driving innovation in women's health across the pharmaceutical, diagnostics, and medical device industries. Through her consultancy, Loken & Associates, Dr. Loken provides medical affairs expertise and fractional Chief Medical Officer (CMO) services, helping early-stage companies bridge the gap between scientific innovation and industry application. She serves as Chief Medical Officer to MenoHealth. · 18 min read · Sep 2026
Medically reviewed by Karla F. Loken, DO, FACOOG on September 20, 2026
Sex after menopause changes for most women, but the specific changes are treatable. Evidence-based guide to GSM, desire, and how to thrive in intimacy.
When hormones are robust, your genitals thrive — they're thick, they lubricate, they're healthy, they're acidic, and the microbiome is on point. When hormone levels start to drop, you start getting urinary frequency or urgency, itching, burning, and dryness — and you may start to have pain with sex. And the craziest thing is that Genitourinary Syndrome of Menopause was only coined in 2014.
If you’re searching for what happens to sex after menopause, you’ve probably been told the changes are inevitable, untreatable, or simply “part of getting older.” That framing is both clinically wrong and culturally damaging. Sex after menopause changes for most women — but the specific changes are well-characterized, mostly treatable, and rarely insurmountable. The women thriving sexually in postmenopause are not exceptions. They’re women who have access to accurate information and effective treatment.
This guide walks through what actually changes biologically and psychologically after menopause, the evidence-based treatments for the most common concerns, and the wider relationship and lifestyle factors that shape sexual well-being in midlife and beyond.
Key takeaways
Changes in sex after menopause are common but specific: vaginal dryness and pain, changes in arousal and lubrication, shifts in desire, and some sensitivity changes are the most frequent.
Genitourinary syndrome of menopause (GSM) — the constellation of vulvovaginal and urinary symptoms — affects roughly half of postmenopausal women and is highly treatable with vaginal estrogen, DHEA, and other options.
Desire changes during menopause aren’t only hormonal — they reflect a mix of biology, sleep, mood, relationship factors, and the cumulative load of midlife. Treating sleep and vasomotor symptoms often improves desire without specifically targeting it.
The Menopause Society 2020 GSM Position Statement and 2022 Hormone Therapy Position Statement support vaginal estrogen as safe and effective for GSM in most postmenopausal women, including (with appropriate clinical input) many breast cancer survivors.
Sexual function after menopause is shaped at least as much by relationship dynamics, communication, and accumulated life context as by hormones. Both axes are worth addressing.
The short answer
For most women, sex changes after menopause but doesn’t end. The most common physical changes are related to genitourinary syndrome of menopause (GSM) — vaginal dryness, thinning of vaginal and vulvar tissue, reduced lubrication, and sometimes pain with intercourse. These changes happen because the vulvovaginal tissues are estrogen-responsive, and sustained estrogen deficiency in postmenopause makes them thinner, less elastic, less vascularized, and more easily irritated.
The good news — which often doesn’t make it into clinical conversations — is that GSM is one of the most treatable conditions in menopause medicine. Low-dose vaginal estrogen, vaginal DHEA, and several non-hormonal options effectively reverse the tissue changes for most women. Treatment can be safely continued long-term in most situations.
Beyond the tissue changes, sexual function in postmenopause is shaped by sleep, mood, vasomotor symptoms, body image, relationship factors, and the cumulative load of midlife. Treating the contributing factors often improves sex more than targeting sex directly. Among women who report dissatisfaction with their sex lives in postmenopause, untreated GSM and unaddressed sleep disruption are two of the most common modifiable contributors.
What actually changes
The physical changes after menopause are well-characterized. Knowing what’s happening helps clarify which changes are biological (and often treatable) versus situational.
Vaginal and vulvar tissue changes (GSM)
There is global consensus that testosterone is safe for menopausal women, that it works well, and that it's safe. Global consensus. Right now in 2025, I don't think we have global consensus on anything — and yet here we are.
Estrogen maintains the thickness, elasticity, vascularity, and lubrication of vaginal and vulvar tissues during reproductive years. When estrogen declines in postmenopause, these tissues progressively thin, lose elasticity, become less vascularized, and produce less lubrication. The result is a constellation of symptoms collectively called genitourinary syndrome of menopause (GSM):
Vaginal dryness
Burning, irritation, or itching
Pain with intercourse (dyspareunia)
Vaginal bleeding after sex (from fragile tissue)
It feels almost like an epidemic — middle-aged women being told testosterone is the miracle drug they've been looking for. It'll give them energy, it'll make them thin, it will improve libido — they've been promised it does everything. That's not what the evidence says.
Reduced sexual responsiveness
Urinary urgency, frequency, or recurrent UTIs
A sensation of vaginal looseness or, paradoxically, narrowing
GSM affects roughly half of postmenopausal women, often appears years after the final period rather than during the transition itself, and — unlike hot flashes — tends to worsen over time without treatment. The Menopause Society’s 2020 GSM Position Statement is the consensus reference and treats GSM as a chronic, progressive condition that responds well to local therapy.
For a deeper dive into GSM specifically, see our pillar on painful sex menopause.
Lubrication and arousal
Beyond chronic GSM tissue changes, acute lubrication during arousal often takes longer and produces less fluid after menopause. This isn’t about desire or attraction — it’s a normal physiological change in the time-course and volume of arousal response. The clinical implication is that intercourse may benefit from longer arousal time, lubricants, and sometimes vaginal estrogen even in women without other GSM symptoms.
Sensation and orgasm
Some women report changes in clitoral and vaginal sensation, time to orgasm, or orgasm intensity after menopause. These changes are usually subtle, often relate more to tissue health and arousal than to capacity for orgasm itself, and frequently improve with treatment of underlying GSM and arousal-time adjustments. Most postmenopausal women retain the capacity for orgasm.
Desire
Desire changes during the menopause transition are well-documented but harder to pin to a single cause. Hormonal contributors include declining estrogen and progesterone and gradual decline in ovarian androgens. Non-hormonal contributors are at least as important: sleep disruption from hot flashes, mood symptoms, body image changes, relationship dynamics, partner factors (for women in partnered relationships), and the cumulative cognitive and emotional load of midlife.
Desire is also context-dependent in ways that often don’t get acknowledged. The standard reproductive-age experience of “spontaneous desire” — wanting sex without a specific trigger — gives way for many women, with or without menopause, to “responsive desire” — desire that emerges in response to specific stimuli, context, or partner cues. This shift is normative, not pathological, and doesn’t mean sex is over. It does mean that the model of “I should feel like having sex spontaneously, and if I don’t, something’s wrong” is a poor fit for what’s actually happening.
What treatments actually work
The treatment landscape for sexual changes after menopause is better than most women have been told. The evidence-supported options sort into a few categories.
For GSM and the tissue changes
Low-dose vaginal estrogen. This is the most effective treatment for GSM, supported by The Menopause Society 2020 GSM and 2022 HT Position Statements, and by NICE Guideline NG23 (updated November 2024). Low-dose vaginal estrogen comes in three FDA-approved forms: vaginal cream, vaginal tablets/inserts, and vaginal rings (a soft ring releasing estradiol for three months). The dose delivered is much lower than systemic hormone therapy, and serum estrogen levels in women using low-dose vaginal estrogen typically remain in the postmenopausal range.
Vaginal estrogen reverses the tissue changes of GSM over weeks to months, restores lubrication and elasticity, reduces dyspareunia, and reduces UTI recurrence. The 2020 GSM Position Statement explicitly states that vaginal estrogen does not require a progestogen for endometrial protection in most clinical scenarios because the systemic estrogen exposure is so low.
The safety question that comes up most often — “doesn’t all estrogen carry the same risks?” — was substantially addressed by Crandall and colleagues’ 2018 analysis in Menopause, which examined vaginal estrogen use in the Women’s Health Initiative Observational Study and found no increased risks of stroke, coronary heart disease, venous thromboembolism, or breast cancer in vaginal estrogen users compared with non-users. This is one of the more reassuring datasets in modern menopause medicine, and it underpins the current consensus that low-dose vaginal estrogen is safe for most postmenopausal women.
For more on the safety picture specifically, see our supporting pillar on is vaginal estrogen safe.
Vaginal DHEA (prasterone). Vaginal DHEA is FDA-approved for dyspareunia due to GSM. It works by being converted locally to estrogens and androgens in vulvovaginal tissue without significantly elevating circulating hormone levels. Multiple randomized trials support its efficacy for dyspareunia. It’s a reasonable alternative for women who prefer to avoid vaginal estrogen or who have a clinical reason to use a non-estrogen option.
Vaginal moisturizers and lubricants. These are non-hormonal first-line options for mild symptoms and often used alongside hormonal therapy for the lubrication needs of intercourse. Moisturizers (used regularly, not just at the time of sex) coat and hydrate vaginal tissue. Lubricants (used at the time of sex) reduce friction. Water-based, silicone-based, and oil-based options each have trade-offs related to texture, longevity, and compatibility with condoms or sex toys.
Ospemifene. An oral selective estrogen receptor modulator (SERM) FDA-approved for dyspareunia due to GSM. It acts as an estrogen agonist in vaginal tissue and reduces dyspareunia in clinical trials. It’s an option for women who prefer an oral route, though it carries its own contraindications.
Vaginal laser and energy-based devices. These have been heavily marketed for GSM and post-menopausal sexual concerns. The FDA has issued cautionary statements about laser and energy-based vaginal devices because the evidence base is much weaker than the marketing suggests, and adverse effects including burning and scarring have been reported. The Menopause Society does not currently endorse these as first-line therapy. Women considering them should be aware that they’re not a proven substitute for vaginal estrogen.
For desire and arousal
Address the contributing factors first. Sleep disruption from vasomotor symptoms, untreated depression and anxiety, untreated GSM (which produces pain that suppresses desire), and unaddressed relationship factors are common contributors to lower desire. Treating these often improves desire without specifically targeting libido. Our guides on menopause insomnia and menopause anxiety cover the relevant treatments.
Systemic hormone therapy can support desire indirectly — by improving sleep, reducing hot flashes, and improving overall well-being — and sometimes directly through effects on arousal and mood. It’s not approved specifically for low desire, but is often part of a regimen that improves sexual function in women with multiple symptoms.
Transdermal testosterone. A 2019 Global Consensus Position Statement on the use of testosterone therapy for women supports the use of low-dose transdermal testosterone for postmenopausal women with hypoactive sexual desire disorder (HSDD), in the context of a comprehensive evaluation. The evidence is strongest for transdermal preparations at physiologic doses; there are no FDA-approved testosterone products for women in the US, so prescribing typically involves off-label use of products formulated for men at much lower doses, or compounded preparations under specialist supervision.
The clinical context matters. Testosterone therapy isn’t a routine prescription, and the evidence base for benefits outside the specific HSDD indication is weaker. It’s reasonable to discuss with a clinician familiar with the consensus criteria.
Flibanserin and bremelanotide. Two FDA-approved medications for premenopausal HSDD. The evidence base for postmenopausal use is more limited; these aren’t typically first-line for postmenopausal women.
Counseling and sex therapy. Often the highest-value intervention for desire concerns is a structured conversation about what desire looks like at this life stage, how it’s changed, and what context supports it. Sex therapy with a clinician trained in the field (search the AASECT directory for certified therapists) can be especially valuable for couples navigating shifts in their sexual relationship.
For partnered sex specifically
Time and context. The arousal time-course changes after menopause; the sex script that worked at 35 may need adjusting. Longer arousal, more focus on non-intercourse intimacy, and more attention to context (privacy, fatigue, mood) often matter more than they did before.
Communication with your partner. Sexual changes are easier to navigate when both partners understand what’s happening biologically and what isn’t. The conversation is often harder than the changes themselves; couples who haven’t talked about sex in years tend to find this part the most uncomfortable. There’s no shortcut around the conversation.
Partner factors. Many partners are also navigating midlife sexual changes — erectile dysfunction, lower libido, fatigue, health conditions. Sexual concerns in midlife relationships are frequently mutual rather than one-sided, even when only one partner brings them up.
What hormone therapy does and doesn’t do
A common misconception is that systemic hormone therapy will fix sexual concerns by itself. The realistic picture is more nuanced.
Systemic hormone therapy — typically estradiol plus a progestogen in women with a uterus — does improve some aspects of sexual function for many women: better sleep, fewer hot flashes, more energy, sometimes improved mood, sometimes improved arousal. It doesn’t fully address GSM (vaginal estrogen is often still needed for the vulvovaginal tissue specifically) and doesn’t directly target desire.
Vaginal estrogen, by contrast, specifically addresses GSM and is often more directly impactful on sexual function in postmenopausal women whose primary concern is pain or dryness. Many women benefit from both — systemic HT for sleep, mood, vasomotor symptoms, and overall well-being, and low-dose vaginal estrogen for the local tissue needs of comfortable sex.
For broader context on the systemic hormone therapy decision, see our pillars on HRT benefits and is HRT safe.
Special situations
Breast cancer survivors. Sexual concerns are common in breast cancer survivors and frequently undertreated because of overcaution around hormone therapy. The actual picture: many breast cancer survivors can safely use low-dose vaginal estrogen for GSM after appropriate clinical input, particularly when GSM is symptomatic and non-hormonal options have been insufficient. The Menopause Society and the Society of Gynecologic Oncology have published nuanced positions supporting this in many clinical scenarios. Decisions should involve the oncology team. Our guide on tamoxifen side effects covers the broader picture for women on endocrine therapy.
Surgical menopause. Women who have had bilateral oophorectomy often have more acute and severe sexual changes because of the abrupt loss of ovarian estrogen and androgens. Hormone therapy in this group has a stronger indication when there are no contraindications. Our guide on surgical menopause covers the post-oophorectomy clinical picture.
Single or new partners. Sexual concerns aren’t only for women in long-term partnerships. Women navigating dating, new relationships, or sex after divorce or widowhood face their own version of these questions, often with less established communication patterns and less existing context. The treatments are the same. The relationship considerations differ.
What this means for you
A practical synthesis for women navigating sex after menopause:
Most of the common physical changes are treatable. GSM responds well to vaginal estrogen, vaginal DHEA, or non-hormonal options. Dryness, pain, and discomfort are not things to “just live with.” The treatments are safe in most clinical situations.
The desire question is more complex but rarely solved by one intervention. Treating sleep, mood, vasomotor symptoms, and GSM often improves desire without specifically targeting it. For persistent desire concerns after those contributors are addressed, testosterone therapy is an option to discuss with a specialist.
The lubrication and arousal time-course change. This isn’t pathological — it’s a normal physiological shift that can be accommodated with adjustments to context, time, and (often) topical or systemic treatment of GSM.
Communication and context matter at least as much as hormones. Sexual function in long-term relationships is shaped by communication, shared expectations, and accumulated relational history more than by any single biological factor. This is true at every age; it’s particularly true in midlife.
Many of the gaps in care are about not asking, not about lack of treatment. Sexual concerns are underaddressed in routine menopause visits because they’re rarely raised. If your clinician doesn’t ask, it’s reasonable to bring up the topic explicitly. Most clinicians have meaningful options to offer once they know what you’re navigating.
When to talk to your doctor
Reasonable triggers for a clinical conversation include:
Vaginal dryness, burning, irritation, or pain — at any point in postmenopause
Pain with intercourse, even if intermittent
Recurrent UTIs or urinary urgency that’s worsened after menopause
Reduced sensation, arousal, or orgasmic response that’s bothering you
Persistent low desire after sleep, mood, and physical concerns have been addressed
Sexual concerns that are interfering with a partnered relationship
Questions about whether vaginal estrogen or hormone therapy is appropriate for your situation, including if you have a history of breast cancer
If you’re preparing for that conversation, our guide on talking to your doctor about menopause covers how to bring sexual concerns in a structured way. Sexual health is a legitimate primary visit topic, not a secondary aside.
Frequently asked questions
Does menopause end your sex life?
For most women, no. The biological changes that happen are well-characterized and largely treatable. The women who report active and satisfying sex lives in postmenopause are not exceptions; they’re often women who have access to accurate information and effective treatment.
Why is sex painful after menopause?
Most commonly, GSM — the constellation of thinning, drying, and reduced lubrication of vulvovaginal tissues from sustained estrogen deficiency. GSM is highly treatable with low-dose vaginal estrogen, vaginal DHEA, or other options. Other causes can include pelvic floor changes, scar tissue, certain medications, and rarely other conditions; persistent pain warrants evaluation.
Is it normal to have lower desire after menopause?
Many women experience desire changes during and after the transition. Whether it’s “normal” or worth treating depends on whether it’s bothering you and your partner (if you have one). Desire is shaped by hormones, sleep, mood, GSM (which produces pain that suppresses desire), and relationship and life context. Addressing the contributing factors often improves desire more than targeting it directly.
Is vaginal estrogen safe long-term?
For most postmenopausal women, yes. Low-dose vaginal estrogen delivers very little systemic estrogen, and the 2018 Crandall analysis of WHI Observational data showed no increased risks of stroke, CHD, VTE, or breast cancer in users. The Menopause Society 2020 GSM Position Statement and 2022 HT Position Statement support long-term use. Most women can safely continue vaginal estrogen as long as they want to, with periodic clinical review.
Can I use vaginal estrogen if I had breast cancer?
Often yes, with appropriate input from your oncology team. The Menopause Society and the Society of Gynecologic Oncology have published nuanced positions supporting use of low-dose vaginal estrogen in many breast cancer survivors with symptomatic GSM when non-hormonal options have been insufficient. This is a conversation to have with a clinician familiar with both menopause and oncology considerations.
Will testosterone improve my desire?
For postmenopausal women with hypoactive sexual desire disorder, the Global Consensus Position Statement supports low-dose transdermal testosterone as a reasonable option after appropriate evaluation. The evidence is strongest for transdermal preparations at physiologic doses. There are no FDA-approved testosterone products for women in the US, so prescribing typically involves off-label use under specialist supervision.
Sources
The Menopause Society. The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society. Menopause. 2020;27(9):976-992.
The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2018;25(1):11-20.
Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the use of testosterone therapy for women. Journal of Clinical Endocrinology and Metabolism. 2019;104(10):4660-4666.
National Institute for Health and Care Excellence. Menopause: identification and management (NG23). Updated November 2024.
Disclaimer
This article is for educational purposes and does not constitute medical advice. Always consult a qualified healthcare provider for guidance on your specific situation. Prescription medications and devices referenced in this article — including vaginal estrogen, vaginal DHEA, ospemifene, systemic hormone therapy, and testosterone therapy — require evaluation by a clinician, have specific contraindications and monitoring requirements, and are not appropriate for everyone. Decisions about hormone therapy in women with a history of breast cancer or other estrogen-sensitive conditions require coordination with the appropriate specialty team.
